Technical and Clinical Outcomes After Transcatheter Edge-to-Edge Repair of Mitral Regurgitation in Male and Female Patients: Is Equality Achieved?

edge‐to‐edge mitral valve repair mitral regurgitation mortality percutaneous mitral valve repair sex

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
28 May 2024
Historique:
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 28 5 2024
Statut: aheadofprint

Résumé

Currently, no clear impact of sex on short- and long-term survival following transcatheter edge-to-edge mitral valve repair (TEER) is evident, although no data are available on postprocedural life expectancy. Our aim was to assess sex-specific differences in outcomes of patients with mitral regurgitation (MR) treated by TEER. Short-term and 5-year outcomes in men and women undergoing TEER between 2011 and 2018 who were included in the large, multicenter, real-world MitraSwiss registry were analyzed. Outcomes were compared stratified by sex and according to MR cause (primary versus secondary). The impact of TEER on postprocedural life expectancy was estimated by relative survival analysis. Among 1142 patients aged 60 to 89 years, 39.8% were women. They were older, with fewer cardiovascular risk factors and lower functional capacity compared with men. Thirty-day mortality was higher in men than in women (3.3% versus 1.1%; odds ratio, 3.16 [95% CI, 1.16-10.7]; TEER is not associated with increased short-term mortality in women, whereas 5-year outcomes are comparable between sexes. Moreover, TEER completely restored normal life expectancy in women with primary MR. A residual excess mortality persists in secondary MR, independently of sex.

Sections du résumé

BACKGROUND BACKGROUND
Currently, no clear impact of sex on short- and long-term survival following transcatheter edge-to-edge mitral valve repair (TEER) is evident, although no data are available on postprocedural life expectancy. Our aim was to assess sex-specific differences in outcomes of patients with mitral regurgitation (MR) treated by TEER.
METHODS AND RESULTS RESULTS
Short-term and 5-year outcomes in men and women undergoing TEER between 2011 and 2018 who were included in the large, multicenter, real-world MitraSwiss registry were analyzed. Outcomes were compared stratified by sex and according to MR cause (primary versus secondary). The impact of TEER on postprocedural life expectancy was estimated by relative survival analysis. Among 1142 patients aged 60 to 89 years, 39.8% were women. They were older, with fewer cardiovascular risk factors and lower functional capacity compared with men. Thirty-day mortality was higher in men than in women (3.3% versus 1.1%; odds ratio, 3.16 [95% CI, 1.16-10.7];
CONCLUSIONS CONCLUSIONS
TEER is not associated with increased short-term mortality in women, whereas 5-year outcomes are comparable between sexes. Moreover, TEER completely restored normal life expectancy in women with primary MR. A residual excess mortality persists in secondary MR, independently of sex.

Identifiants

pubmed: 38804217
doi: 10.1161/JAHA.123.032706
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e032706

Auteurs

Luigi Biasco (L)

Department of Biomedical Sciences University of Italian Switzerland Lugano Switzerland.
Azienda Sanitaria Locale Torino 4 Turin Italy.

Gregorio Tersalvi (G)

Division of Cardiology Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale Lugano Switzerland.

Catherine Klersy (C)

Service of Biostatistics & Clinical Trial Center Fondazione IRCCS Policlinico San Matteo Pavia Italy.

Giovanni Benfari (G)

Division of Cardiology, Department of Medicine University of Verona Verona Italy.

Patric Biaggi (P)

Heart Clinic Zurich, Hirslanden Zurich Switzerland.

Roberto Corti (R)

Heart Clinic Zurich, Hirslanden Zurich Switzerland.

Moreno Curti (M)

Service of Biostatistics & Clinical Trial Center Fondazione IRCCS Policlinico San Matteo Pavia Italy.

Oliver Gaemperli (O)

Heart Clinic Zurich, Hirslanden Zurich Switzerland.

Raban Jeger (R)

Division of Cardiology Triemli Hospital Zürich and University of Basel Basel Switzerland.

Francesco Maisano (F)

Division of Cardiovascular Surgery San Raffaele University Hospital Milano Milan Italy.

Olivier Mueller (O)

Division of Cardiology University Hospital Lausanne Lausanne Switzerland.

Barbara Naegeli (B)

Division of Cardiology Klinik Im Park Zürich Switzerland.

Stephane Noble (S)

Division of Cardiology University Hospital Geneve Geneva Switzerland.

Fabien Praz (F)

Division of Cardiology University Hospital Bern Bern Switzerland.

Stefan Toggweiler (S)

Division of Cardiology, Kantonsspital Luzern Lucerne Switzerland.

Marco Valgimigli (M)

Department of Biomedical Sciences University of Italian Switzerland Lugano Switzerland.
Division of Cardiology Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale Lugano Switzerland.

Yvonne Cristoforetti (Y)

Department of Biomedical Sciences University of Italian Switzerland Lugano Switzerland.

Maurice Enriquez-Sarano (M)

Valve Science Research Center Minneapolis Heart Institute Minneapolis MN USA.

Giovanni Pedrazzini (G)

Department of Biomedical Sciences University of Italian Switzerland Lugano Switzerland.
Division of Cardiology Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale Lugano Switzerland.

Classifications MeSH